Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus;Recomendaciones para la utilización de biomarcadores de imagen PET en el proceso diagnóstico de las enfermedades neurodegenerativas que cursan con demencia: Documento de consenso SEMNIM y SEN

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 34, Issue 5, 2015, Pages 303-313

  Arbizu, J ^a   Garcia Ribas G ^b   Carrio I ^c   Garrastachu, P ^d   Martinez Lage P ^e   Molinuevo, J L ^f  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

^e Centro de Investigación y Terapias Avanzadas   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

18F FDG; Alzheimer's disease; Amyloid imaging; Dementia; Mild cognitive impairment; PET imaging biomarkers; Prodromal Alzheimer disease

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; CARBON; FLUORINE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; THIAZOLE DERIVATIVE;

ARTICLE; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; POSITRON EMISSION TOMOGRAPHY; SYNAPTIC POTENTIAL; SYSTEMATIC REVIEW; ALZHEIMER DISEASE; BRAIN CHEMISTRY; CONSENSUS DEVELOPMENT; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; HUMAN; NEUROIMAGING; PRACTICE GUIDELINE; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; DEMENTIA; EARLY DIAGNOSIS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; NEURODEGENERATIVE DISEASES; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84938750107     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2015.03.002     Document Type: Article

References (98)

1. Molinuevo J.L., Peña-Casanova J. Guía oficial para la práctica clínica en demencias: conceptos, criterios y recomendaciones, 2009. Prous Science 2009.
2. Garre-Olmo J., Lopez-Pousa S., Monserrat-Vila S., Pericot-Nierga I., Turon-Estrada A., Lax-Pericall C. The feasibility of a registry of dementias: Clinical features and diagnostic coverage. Rev Neurol. 2007, 44:385-391.
3. Wilkinson D., Stave C., Keohane D., Vincenzino O. The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: A multinational survey. J Int Med Res. 2004, 32:149-159.
4. Sternberg S.A., Wolfson C., Baumgarten M. Undetected dementia in community-dwelling older people: The Canadian study of health and aging. J Am Geriatr Soc. 2000, 48:1430-1434.
5. Martinez-Lage P., Frölich L., Knox S., Berthet K. Assessing physician attitudes and perceptions of Alzheimer's disease across Europe. J Nutr Health Aging. 2010, 14:537-544.
6. Prince M., Bryce R., Ferr C. Alzheimer's disease international world Alzheimer report 2011: The benefits of early diagnosis and intervention. Institute of Psychiatry, King's College London. Alzheimer's Disease International 2011.
7. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
8. Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol. 2014, 13:614-629.
9. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
10. Sperling R.A., Johnson K.A. Dementia: New criteria but no new treatments. Lancet Neurol. 2012, 11:4-5.
11. Yuan Y., Gu Z.X., Wei W.S. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: A meta-analysis. AJNR Am J Neuroradiol. 2009, 30:404-410.
12. Kawachi T., Ishii K., Sakamoto S., Sasaki M., Mori T., Yamashita F., et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2006, 33:801-809.
13. De Santi S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001, 22:529-539.
14. Messa C., Perani D., Lucignani G., Zenorini A., Zito F., Rizzo G., et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: Comparison with fluorine-18-FDG PET. J Nucl Med. 1994, 35:210-216.
15. 18F-FDG PET/CT scan. Rev Esp Med Nucl. 2011, 30:301-306.
16. Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011, 134:2456-2477.
17. Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., et al. Classification of primary progressive aphasia and its variants. Neurology. 2011, 76:1006-1014.
18. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with lewy bodies: Third report of the DLB consortium. Neurology. 2005, 65:1863-1872.
19. Magistretti P.J., Pellerin L., Rothman D.L., Shulman R.G. Energy on demand. Science. 1999, 283:496-497.
20. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
21. Chetelat G., Desgranges B., Landeau B., Mezenge F., Poline J.B., de la Sayette V., et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain. 2008, 131:60-71.
22. Varrone A., Asenbaum S., vander Borght T., Booij J., Nobili F., Någren K., et al. EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2. Eur J Nucl Med Mol Imaging. 2009, 36:2103-2110.
23. Martí-Climent J.M., Prieto E., López Lafuente J., Arbizu J. Neuroimagen: Fundamentos técnicos y prácticos. Rev Esp Med Nucl. 2010, 29:189-210.
24. Frisoni G.B., Bocchetta M., Chetelat G., Rabinovici G.D., de Leon M.J., Kaye J., et al. Imaging markers for Alzheimer disease: Which vs. how. Neurology. 2013, 81:487-500.
25. Friston K.J., Holmes A.P., Worsley K.J., Poline J., Frith C.D., Frackowiak R.S. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp. 1994, 2:189-210.
26. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995, 36:1238-1248.
27. Herholz K., Salmon E., Perani D., Baron J., Holthoff V., Frölich L., et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002, 17:302-316.
28. Chen K., Ayutyanont N., Langbaum J., Fleisher A.S., Reschke C., Lee W., et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage. 2011, 56:52-60.
29. Arbizu J., Prieto E., Martínez-Lage P., Martí-Climent J., García-Granero M., Lamet I., et al. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. Eur J Nucl Med Mol Imaging. 2013, 40:1394-1405.
30. Panegyres P.K., Rogers J.M., McCarthy M., Campbell A., Wu J.S. Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: A prospective, community-based study. BCM Neurology. 2009, 9:41.
31. Yamane T., Ikari Y., Nishio T., Ishii K., Ishii K., Kato T., et al. Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: Inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol. 2014, 35:244-249.
32. Caroli A., Prestia A., Chen K., Ayutyanont N., Landau S.M., Madison C.M., et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: Head-to-head comparison. J Nucl Med. 2012, 53:592-600.
33. Roberts R.O., Knopman D.S., Cha R.H., Mielke M.M., Pankratz V.S., Boeve B.F., et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med. 2014, 55:759-764.
34. Knopman D., Jack C.J., Wiste H., Lundt E., Weigand S., Vemuri P., et al. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging. 2014, 35:2096-2106.
35. Ossenkoppele R., van der Flier W.M., Zwan M.D., Adriaanse S.F., Boellaard R., Windhorst A.D., et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology. 2013, 80:359-365.
36. Ewers M., Insel P.S., Stern Y., Weiner M.W. Alzheimer's Disease Neuroimaging Initiative (ADNI). Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology. 2013, 80:1194-1201.
37. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with pittsburgh compound-B. Ann Neurol. 2004, 55:306-319.
38. Forsberg A., Juréus A., Cselényi Z., Eriksdotter M., Freund-Levi Y., Jeppsson F., et al. Low background and high contrast PET imaging of amyloid-β with [11C] AZD2995 and [11C] AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013, 40:580-593.
39. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., et al. PIB is a non-specific imaging marker of amyloid-beta (abeta) peptide-related cerebral amyloidosis. Brain. 2007, 130:2607-2615.
40. Clark C.M., Pontecorvo M.J., Beach T.G., Bedell B.J., Coleman R.E., Doraiswamy P.M., et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study. Lancet Neurol. 2012, 11:669-678.
41. Leinonen V., Rinne J., Virtanen K., Eskola O., Rummukainen J., Huttunen J., et al. Positron emission tomography with [18F] flutemetamol and [11C] PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol. 2013, 20:1043-1052.
42. Villemagne V.L., Mulligan R.S., Pejoska S., Ong K., Jones G., O'Keefe G., et al. Comparison of 11C-PiB and 18F-florbetaben for aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012, 39:983-989.
43. Herholz K., Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011, 10:667-670.
44. Landau S.M., Breault C., Joshi A.D., Pontecorvo M., Mathis C.A., Jagust W.J., et al. Amyloid-beta imaging with pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods. J Nucl Med. 2013, 54:70-77.
45. Vandenberghe R., van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol. 2010, 68:319-329.
46. Camus V., Payoux P., Barré L., Desgranges B., Voisin T., Tauber C., et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012, 39:621-631.
47. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., et al. 11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006, 67:446-452.
48. Barthel H., Luthardt J., Becker G., Patt M., Hammerstein E., Hartwig K., et al. Individualized quantification of brain β-amyloid burden: Results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011, 38:1702-1714.
49. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., et al. Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol Aging. 2010, 31:1275-1283.
50. Bloudek L.M., Spackman D.E., Blankenburg M., Sullivan S.D. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 2011, 26:627-645.
51. Bohnen N.I., Djang D.S., Herholz K., Anzai Y., Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: A review of the recent literature. J Nucl Med. 2012, 53:59-71.
52. Patwardhan M.B., McCrory D.C., Matchar D.B., Samsa G.P., Rutschmann O.T. Alzheimer disease: Operating characteristics of PET-A meta-analysis 1. Radiology. 2004, 231:73-80.
53. Mosconi L., Tsui W.H., Pupi A., de Santi S., Drzezga A., Minoshima S., et al. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med. 2007, 48:1129-1134.
54. Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008, 49:390-398.
55. McMurtray A.M., Licht E., Yeo T., Krisztal E., Saul R.E., Mendez M.F. Positron emission tomography facilitates diagnosis of early-onset Alzheimer's disease. Eur Neurol. 2008, 59:31-37.
56. Ng D., Jacobs M., Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med. 2006, 31:373-375.
57. Dobert N., Pantel J., Frolich L., Hamscho N., Menzel C., Grunwald F. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: Metabolic index and perfusion index. Dement Geriatr Cogn Disord. 2005, 20:63-70.
58. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung de Aburto M.A., Chen W., et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001, 286:2120-2127.
59. Jagust W., Reed B., Mungas D., Ellis W., Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia. Neurology. 2007, 69:871-877.
60. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011, 305:275-283.
61. Barthel H., Sabri O. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011, 26:117-121.
62. Newberg A.B., Arnold S.E., Wintering N., Rovner B.W., Alavi A. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med. 2012, 53:902-907.
63. Sánchez-Juan P., Ghosh P., Hagen J., Gesierich B., Henry M., Grinberg L., et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014, 82:230-238.
64. Lowe V.J., Peller P.J., Weigand S.D., Montoya Quintero C., Tosakulwong N., Vemuri P., et al. Application of the national institute on aging-Alzheimer's association AD criteria to ADNI. Neurology. 2013, 80:2130-2137.
65. Rabinovici G.D., Rosen H.J., Alkalay A., Kornak J., Furst A.J., Agarwal N., et al. Amyloid vs. FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011, 77:2034-2042.
66. Ossenkoppele R., Prins N.D., Pijnenburg Y.A., Lemstra A.W., van der Flier Wiesje M., Adriaanse S.F., et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013, 9:414-421.
67. Mielke R., Kessler J., Szelies B., Herholz K., Wienhard K., Heiss W. Normal and pathological aging-findings of positron-emission-tomography. J Neural Transm. 1998, 105:821-837.
68. Cho H., Seo S., Kim J., Suh M., Lee J., Choe Y., et al. Amyloid deposition in early onset versus late onset Alzheimer's disease. J Alzheimers Dis. 2013, 35:813-821.
69. Ossenkoppele R., Zwan M.D., Tolboom N., van Assema D.M., Adriaanse S.F., Kloet R.W., et al. Amyloid burden and metabolic function in early-onset Alzheimer's disease: Parietal lobe involvement. Brain. 2012, 135:2115-2125.
70. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010, 75:230-238.
71. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012, 72:578-586.
72. Okello A., Koivunen J., Edison P., Archer H.A., Turkheimer F.E., Nagren K., et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology. 2009, 73:754-760.
73. Zhang S., Han D., Tan X., Feng J., Guo Y., Ding Y. Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012, 66:185-198.
74. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., et al. Longitudinal assessment of aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011, 69:181-192.
75. Matias-Guiu J.A., Cabrera-Martín M.N., García-Ramos R., Moreno-Ramos T., Valles-Salgado M., Carreras J.L., et al. Evaluation of the new consensus criteria for the diagnosis of primary progressive aphasia using fluorodeoxyglucose positron emission tomography. Dement Geriatr Cogn Disord. 2014, 38:147-152.
76. Kerklaan B.J., Berckel B.N., Herholz K., Dols A., Flier W.M., Scheltens P., et al. The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2014.
77. Villemagne V.L., Fodero-Tavoletti M.T., Pike K.E., Cappai R., Masters C.L., Rowe C.C. The ART of loss: Aβ imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol. 2008, 38:1-15.
78. Rabinovici G.D., Jagust W.J., Furst A.J., Ogar J.M., Racine C.A., Mormino E.C., et al. Aβ amyloid and glucose metabolism in 3 variants of primary progressive aphasia. Ann Neurol. 2008, 64:388-401.
79. Drzezga A., Grimmer T., Henriksen G., Stangier I., Perneczky R., Diehl-Schmid J., et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008, 39:619-633.
80. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007, 22:1689-1707.
81. Dubois B., Burn D., Goetz C., Aarsland D., Brown R.G., Broe G.A., et al. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Mov Disord. 2007, 22:2314-2324.
82. Vander Borght T., Minoshima S., Giordani B., Foster N.L., Frey K.A., Berent S., et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med. 1997, 38:797-802.
83. Pappata S., Santangelo G., Aarsland D., Vicidomini C., Longo K., Bronnick K., et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology. 2011, 77:1357-1362.
84. Garcia-Garcia D., Clavero P., Salas C.G., Lamet I., Arbizu J., Gonzalez-Redondo R., et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging. 2012, 39:1767-1777.
85. 18F] FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord. 2010, 16:666-670.
86. Arbizu J., Luquin M., Abella J., de la Fuente-Fernández R., Fernandez-Torrón R., García-Solís D., et al. Functional neuroimaging in the diagnosis of patients with parkinsonism: Update and recommendations for clinical use. Rev Esp Med Nucl. 2014, 33:215-226.
87. Teune L.K., Bartels A.L., de Jong B.M., Willemsen A., Eshuis S.A., de Vries J.J., et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010, 25:2395-2404.
88. Burrell J.R., Hornberger M., Villemagne V.L., Rowe C.C., Hodges J.R. Clinical profile of PiB-positive corticobasal syndrome. PloS one. 2013, 8:e61025.
89. Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., Kuhl D.E. Alzheimer's disease versus dementia with lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001, 50:358-365.
90. 18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci. 2012, 314:111-119.
91. Lim S.M., Katsifis A., Villemagne V.L., Best R., Jones G., Saling M., et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with lewy bodies. J Nucl Med. 2009, 50:1638-1645.
92. Kantarci K., Lowe V.J., Boeve B.F., Weigand S.D., Senjem M.L., Przybelski S.A., et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012, 33:2091-2105.
93. Laforce R., Buteau J.P., Paquet N., Verret L., Houde M., Bouchard R.W. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study. Am J Alzheimers Dis Other Demen. 2010, 25:324-332.
94. Schipke C.G., Peters O., Heuser I., Grimmer T., Sabbagh M.N., Sabri O., et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord. 2012, 33:416-422.
95. Frederiksen K.S., Hasselbalch S.G., Hejl A.M., Law I., Hojgaard L., Waldemar G. Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra. 2012, 2:610-621.
96. Foster N.L., Heidebrink J.L., Clark C.M., Jagust W.J., Arnold S.E., Barbas N.R., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007, 130:2616-2635.
97. Grundman M., Pontecorvo M.J., Salloway S.P., Doraiswamy P.M., Fleisher A.S., Sadowsky C.H., et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013, 27:4-15.
98. Booij J., Arbizu J., Darcourt J., Hesse S., Nobili F., Payoux P., et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013, 40:1122-1125.